CNR1 and obesity due to melanocortin 4 receptor deficiency: To develop more specific and safe pharmacological interventions for the treatment of overeating, the recently presented molecular ultrastructure of human CB1 may deliver new opportunities for the design of next-generation CB1 directing pharmaceuticals as novel anti-obesity drugs (Hua et al., 2016; Shao et al., 2016).